-
Findings Call Into Question the Value of Local Consolidative Therapy in Metastatic NSCLC After Dual Immune Checkpoint Blockade
The randomized LONESTAR trial showed no progression-free or overall survival benefit with local consolidative therapy after immune checkpoint blockade-based induction treatment in metastatic NSCLC without actionable genomic alterations.
More News from #WCLC26
-
Zidesamtinib Demonstrates a High Objective Response Rate in TKI-Naïve Patients with Advanced ROS1-Positive NSCLC
Researcher Alexander Drilon, MD, said at a median follow-up duration of 15.2 months, the objective response rate was 94%, and the complete response rate was 15%.
-
T-DXd Poised for Shift to Frontline in HER2-Mutated Metastatic NSCLC
Julia Rotow, MD, said first-line trastuzumab deruxtecan monotherapy significantly improved progression-free survival compared with chemo-immunotherapy in the global phase III DESTINY-Lung04 trial.
